Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

被引：2

作者：

Mateos, Maria-Victoria ^{[1
]}

Usmani, Saad Z. ^{[2
]}

Grosicki, Sebastian ^{[3
]}

Vorobyev, Vladimir I. ^{[4
]}

Spicka, Ivan ^{[5
]}

Hungria, Vania T. M. ^{[6
]}

Korenkova, Sibirina ^{[7
]}

Bahlis, Nizar ^{[8
]}

Flogegard, Max ^{[9
]}

Blade, Joan ^{[10
]}

Moreau, Philippe ^{[14
]}

Kaiser, Martin F. ^{[11
]}

Iida, Shinsuke ^{[12
]}

Laubach, Jacob P. ^{[13
]}

Masterson, Tara ^{[15
]}

Lantz, Kristen Anne ^{[15
]}

O'Rourke, Lisa ^{[15
]}

Qin, Xiang ^{[16
]}

Parasrampuria, Dolly A. ^{[15
]}

Heuck, Christoph ^{[15
]}

Qi, Ming ^{[15
]}

Nahi, Hareth ^{[17
]}

机构：

[1] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[3] Med Univ Silesian, Sch Publ Hlth, Dept Hematol & Canc Prevent, Katowice, Poland

[4] SP Botkin City Clin Hosp, Moscow, Russia

[5] Gen Fac Hosp, Prague, Czech Republic

[6] Santa Casa Med Sch, Sao Paulo, Brazil

[7] Kiev Ctr Bone Marrow Transplantat, Kiev, Ukraine

[8] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[9] Falun Gen Hosp, Dept Internal Med, Falun, Sweden

[10] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[11] Inst Canc Res, Div Mol Pathol, Sutton, Surrey, England

[12] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan

[13] Harvard Med Sch, Dana Farber Canc Inst, Dept Hematol & Oncol, Boston, MA 02115 USA

[14] Univ Hosp Nantes, Nantes, France

[15] Janssen Res & Dev LLC, Spring House, PA USA

[16] Janssen Res & Dev LLC, Raritan, NJ USA

[17] Karolinska Inst, Karolinska Univ Hosp, Div Hematol, Dept Med, Huddinge, Sweden

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122501

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1906

引用

页数：5

共 50 条

[41] KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).
Shah, Jatin J.
Jagannath, Sundar
Mateos, Maria-Victoria
Palumbo, Antonio
Kher, Uma
Marinello, Patricia Maria
San Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[42] Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Chari, Ajai
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Nahi, Hareth
Tang, Jie
Hellemans, Peter
Tromp, Brenda
Clemens, Pamela L.
Farnsworth, Andrew
San-Miguel, Jesus F.
Usmani, Saad Z.
BLOOD, 2018, 132
[43] A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
Weisel, Katja
Bentur, Ohad
Van Domelen, Dane
Boccadoro, Mario
Sonneveld, Pieter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S216 - S217
[44] Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study
Nahi, Hareth
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Oriol, Albert
Plesner, Torben
Bandyopadhyay, Nibedita
Hellemans, Peter
Tromp, Brenda
Nnane, Ivo
Zemlickis, Donna
Chari, Ajai
Moreau, Philippe
LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 468 - 472
[45] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Usmani, Saad Z.
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Gavriatopoulou, Maria
Oriol, Albert
Rabin, Neil
Nooka, Ajay
Qi, Ming
Beksac, Meral
Jakubowiak, Andrzej
Ding, Bifeng
Zahlten-Kumeli, Anita
Yusuf, Akeem
Dimopoulos, Meletios
LANCET ONCOLOGY, 2022, 23 (01): : 65 - 76
[46] A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)
Niederwieser, Dietger
Richardson, Paul
Attal, Michel
Rajkumar, Vincent
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulosu, Meletios
Huan, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Mace, Sandrine
Prince, H. Miles
Corzo, Kathryn P.
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth C.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 40 - 41
[47] Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3trial
Dimopoulos, Meletios A.
Terpos, Evangelos
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Baldini, Luca
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria -Victoria
Einsele, Hermann
Orfanidis, Ioannis
Kampfenkel, Tobias
Liu, Weiping
Wang, Jianping
Kosh, Michele
Tran, Namphuong
Carson, Robin
Sonneveld, Pieter
LANCET HAEMATOLOGY, 2023, 10 (10): : E813 - E824
[48] Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Clemens, Pamela L.
Xu, Steven
Luo, Melody
Chari, Ajai
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
San-Miguel, Jesus F.
Sun, X. Yu-Nien
Farnsworth, Andrew
Masterson, Tara
Hellemans, Peter
Qi, Ming
Nahi, Hareth
BLOOD, 2018, 132
[49] ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Dimopoulos, M.
Lonial, S.
Palumbo, A.
White, D.
Grosicki, S.
Spicka, I.
Walter-Croneck, A.
Moreau, P.
Mateos, M. -V.
Magen, H.
Belch, A.
Reece, D.
Beksac, M.
Spencer, A.
Oakervee, H.
Taniwaki, M.
Roellig, C.
Wu, K. L.
Singhal, A.
San Miguel, J.
Matsumoto, M.
Katz, J.
Bleickardt, E.
Poulart, V.
Richardson, P.
HAEMATOLOGICA, 2015, 100 : 173 - 173
[50] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Dimopoulos, Meletios A.
Moreau, Philippe
Palumbo, Antonio
Joshua, Douglas
Pour, Ludek
Hajek, Roman
Facon, Thierry
Ludwig, Heinz
Oriol, Albert
Goldschmidt, Hartmut
Rosinol, Laura
Straub, Jan
Suvorov, Aleksandr
Araujo, Carla
Rimashevskaya, Elena
Pika, Tomas
Gaidano, Gianluca
Weisel, Katja
Goranova-Marinova, Vesselina
Schwarer, Anthony
Minuk, Leonard
Masszi, Tamas
Karamanesht, Ievgenii
Offidani, Massimo
Hungria, Vania
Spencer, Andrew
Orlowski, Robert Z.
Gillenwater, Heidi H.
Mohamed, Nehal
Feng, Shibao
Chng, Wee-Joo
LANCET ONCOLOGY, 2016, 17 (01): : 27 - 38

← 1 2 3 4 5 →